NASDAQ:XENTIntersect ENT Stock Price, Forecast & News

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XENT shares have decreased by 48.1% and is now trading at $11.15. View which stocks have been most impacted by Coronavirus.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 1 sell rating, 8 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Intersect ENT.

Intersect ENT is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Intersect ENT.

Intersect ENT Inc (NASDAQ:XENT) issued its quarterly earnings data on Monday, May, 11th. The medical equipment provider reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.10. The medical equipment provider had revenue of $19.83 million for the quarter, compared to the consensus estimate of $19.70 million. Intersect ENT had a negative net margin of 48.61% and a negative return on equity of 43.72%. View Intersect ENT's earnings history.

Intersect ENT issued an update on its first quarter 2020 After-Hours earnings guidance on Monday, April, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $19.5-19.8 million, compared to the consensus revenue estimate of $26.6 million.

10 equities research analysts have issued 1-year price targets for Intersect ENT's shares. Their forecasts range from $10.00 to $30.00. On average, they anticipate Intersect ENT's stock price to reach $19.38 in the next year. This suggests a possible upside of 73.8% from the stock's current price. View analysts' price targets for Intersect ENT.

News coverage about XENT stock has been trending somewhat negative this week, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Intersect ENT earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned news headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news aboutIntersect ENT.

Intersect ENT saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 1,130,000 shares, an increase of 56.0% from the April 30th total of 724,200 shares. Based on an average daily volume of 1,020,000 shares, the short-interest ratio is currently 1.1 days. Approximately 3.6% of the company's stock are short sold. View Intersect ENT's Current Options Chain.

Some companies that are related to Intersect ENT include Shockwave Medical (SWAV), Cardiovascular Systems (CSII), Luminex (LMNX), Axonics Modulation Technologies (AXNX), Silk Road Medical (SILK), Atrion (ATRI), Tactile Systems Technology (TCMD), Cerus (CERS), Cryolife (CRY), OraSure Technologies (OSUR), Orthopediatrics (KIDS), Orthofix Medical (OFIX), GenMark Diagnostics (GNMK), LeMaitre Vascular (LMAT) and Vapotherm (VAPO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intersect ENT investors own include SEASPAN CORP/SH SH (SSW), Textainer Group (TGH), iShares MSCI Brazil ETF (EWZ), COSTAMARE INC/SH (CMRE), Mimecast (MIME), Air Transport Services Group (ATSG), EOG Resources (EOG), AbbVie (ABBV), Gilead Sciences (GILD) and Netflix (NFLX).

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Intersect ENT's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (8.03%), UBS Group AG (6.78%), Jennison Associates LLC (2.74%), State Street Corp (2.22%), Nuveen Asset Management LLC (1.80%) and Rock Springs Capital Management LP (1.54%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard A Meier, Richard E Kaufman, Robert H Binney, Jr, Susan P Stimson and Thomas A West. View institutional ownership trends for Intersect ENT.

XENT stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Rock Springs Capital Management LP, Waddell & Reed Financial Inc., Deutsche Bank AG, Nuveen Asset Management LLC, BlackRock Inc., Tudor Investment Corp Et Al, and Invesco Ltd.. Company insiders that have sold Intersect ENT company stock in the last year include Robert H Binney, Jr, and Susan P Stimson. View insider buying and selling activity for Intersect ENT.

XENT stock was purchased by a variety of institutional investors in the last quarter, including UBS Group AG, JPMorgan Chase & Co., Two Sigma Advisers LP, Two Sigma Investments LP, Balyasny Asset Management LLC, Jennison Associates LLC, Orbimed Advisors LLC, and AQR Capital Management LLC. Company insiders that have bought Intersect ENT stock in the last two years include Dana G Jr Mead, Richard A Meier, and Thomas A West. View insider buying and selling activity for Intersect ENT.

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XENT stock can currently be purchased for approximately $11.15.

Intersect ENT has a market capitalization of $363.04 million and generates $109.14 million in revenue each year. The medical equipment provider earns $-42,990,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Intersect ENT employs 393 workers across the globe.

The official website for Intersect ENT is www.intersectent.com.

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]